GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Everest Organics Ltd (BOM:524790) » Definitions » EBIT

Everest Organics (BOM:524790) EBIT : ₹-3 Mil (TTM As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Everest Organics EBIT?

Everest Organics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ₹21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Everest Organics's annualized ROC % for the quarter that ended in Sep. 2024 was 6.20%. Everest Organics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 8.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Everest Organics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -0.15%.


Everest Organics EBIT Historical Data

The historical data trend for Everest Organics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Organics EBIT Chart

Everest Organics Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only 160.95 192.85 43.56 30.29 54.53

Everest Organics Quarterly Data
Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.26 15.99 7.81 -48.01 20.98

Competitive Comparison of Everest Organics's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Everest Organics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Organics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Everest Organics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Everest Organics's EV-to-EBIT falls into.



Everest Organics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Organics  (BOM:524790) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Everest Organics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=78.296 * ( 1 - 0.92% )/( (1263.811 + 1239.499)/ 2 )
=77.5756768/1251.655
=6.20 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2289.363 - 1187.075 - ( 10.285 - max(0, 1687.199 - 1525.676+10.285))
=1263.811

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2198.556 - 1142.097 - ( 10.019 - max(0, 1622.261 - 1439.221+10.019))
=1239.499

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Everest Organics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=83.928/( ( (712.68 + max(256.368, 0)) + (705.87 + max(206.147, 0)) )/ 2 )
=83.928/( ( 969.048 + 912.017 )/ 2 )
=83.928/940.5325
=8.92 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(982.891 + 465.474 + 67.026) - (1187.075 + 0 + 71.948)
=256.368

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(912.16 + 458.832 + 58.21) - (1142.097 + 0 + 80.958)
=206.147

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Everest Organics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-3.226/2199.614
=-0.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Organics EBIT Related Terms

Thank you for viewing the detailed overview of Everest Organics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Organics Business Description

Traded in Other Exchanges
N/A
Address
Opposite Madhapur Police Station Road, 1st Floor, Amar Co-Operative Society, Lakeview Plaza, Plot No. 127 and 128, Near Durgam Cheruvu, Madhapur, Hyderabad, TG, IND, 500 033
Everest Organics Ltd is a pharmaceutical company. It is focused on manufacturing active pharmaceutical ingredients and intermediaries. The products offered by the company include Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole, and others. The company operates in one primary business segment namely Active Pharmaceutical Ingredients (API) and their intermediaries. Geographically, it derives a majority of its revenue from India.

Everest Organics Headlines

No Headlines